Xyrem Articles
Opportunities for Pharma in narcolepsy
20 February 2012
EMA advisory says no to UCB's Xyrem for fibromyalgia
18 March 2011
US FDA panel says overwhelming “no” to using Jazz Pharma’s date-rape type drug for fibromyalgia
23 August 2010
Enrollment complete in Ph III trial of Jazz' fibromyalgia drug
19 January 2009
Jazz/UCB drug meets endpoints in Ph III trial
1 December 2008
Jazz' net loss deepens to $46.7M in 1st qtr
26 May 2008
Orphan Medical fined $20M in Xyrem case
23 July 2007
EC approves UCB's Xyrem
19 March 2007
UCB's Xyrem gets CHMP recommendation
5 February 2007
Valeant licenses Canada rights to Xyrem
22 January 2007
UCB gets expanded Xyrem marketing license by Jazz
9 October 2006
Jazz' cataplexy drug gains EU approval
19 December 2005
Stock Commentary - Europe
11 July 2005
UCB's Xyrem moves closer to EU approval
11 July 2005
Jazz completes Orphan Medical buy
4 July 2005
Jazz Pharma to acquire Orphan Medical in $122.6M deal
25 April 2005
Orphan Medical sees good prospects for Xyrem
28 February 2005
Orphan's net loss climbs for 1st-qtr
3 May 2004
Celltech's Xyrem on track in EU
12 April 2004
Orphan reports 2003 revenue dip of 4%
1 March 2004
Celltech acquires rights to Xyrem from Orphan Medical
3 November 2003
Orphan Medical provides positive outlook guidance
13 January 2003
FDA asks for more data on Orphan's Xyrem
22 April 2002
Orphan Medical completes $41.1M placement
11 December 2001
FDA accepts Orphan's amended Xyrem NDA
29 October 2001
Orphan submits ammended Xyrem NDA to FDA
11 October 2001
FDA accepts Orphan's amended Xyrem NDA
30 August 2001
FDA panel votes in favor of Orphan's Xyrem
8 June 2001
Positive data for Orphan's Xyrem
30 May 2001
Orphan's Xyrem for narcolepsy - advisory meeting
17 April 2001
Orphan's narcolepsy drug delayed at FDA
5 April 2001
Panel meeting delay for Orphan Medical
5 March 2001
Orphan Medical files NDA for Xyrem
5 October 2000
Orphan Medical looks to future with Xyrem
27 January 2000
Orphan Medical's IND for Xyrem approved
21 December 1998
New Narcolespy Drug From Orphan
25 March 1998
Showing 1-41 of 41 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
